|
|
|
|
 |
SAN DIEGO--- Structural GenomiX Receives $48.5 Million Award From NIH |
| 7/1/2005 @ 6:25 PM
print this article -
email to a friend -
join our eNewsletter
|
 |
Privately-held Structural GenomiX, Inc. (SGX) today announced receipt of a $48.5 million National Institutes of Health (NIH) Cooperative Agreement Award from the National Institute of General Medical Sciences (NIGMS) www.nigms.nih.gov. The award is one of ten the NIH announced today as part of its Protein Structure Initiative (PSI), which aims to facilitate the discovery of the three-dimensional structures of proteins to help reveal their role in disease and aid in the design of new medicines.
The NIH award provides five years of renewed funding for a consortium administered by SGX, the New York Structural GenomiX Research Consortium (NYSGXRC) (www.nysgxrc.org). SGX expects to retain approximately 50 percent of the funding with the remainder to be distributed to institution collaborators. The NYSGXRC is an internationally-recognized, industry-academic structural genomics center that was established by Dr. Stephen K. Burley, SGX's chief scientific officer and senior vice president, during the pilot study phase of the PSI. Additional participants in the NYSGXRC include scientists at Albert Einstein College of Medicine, Brookhaven National Laboratory, Columbia University, and the University of California at San Francisco.
"We are partnering with some of the finest medical research institutions in the world," commented Burley.
Under Dr. Burley as principal investigator, SGX will lead the overall research efforts under this NIH Award and will be responsible for primary oversight and administration of activities by the institution collaborators, as well as all gene cloning and expression, purification, and biophysical characterization of target proteins. SGX will use its proprietary technology platform to produce high quality and well characterized proteins for crystallization and structure determination. In addition, SGX will provide access to its state-of-the-art X-ray beamline at the Advanced Photon Source, Argonne National Laboratory for structure determination efforts.
"We are pleased that SGX's comprehensive protein structure research efforts to date laid the groundwork for this NIH award," stated Dr. Burley. "Understanding of protein structures plays an integral role in comprehending complex biological systems and in developing the next generation of drug targets and medicines. This award gives SGX an unprecedented opportunity to favorably impact both basic biomedical research and the drug discovery process."
About SGX
SGX discovers and develops innovative cancer therapeutics. SGX's lead product candidate is Troxatyl(TM), a novel cancer therapeutic currently in Phase 2/3 clinical trials for the treatment of Acute Myelogenous Leukemia and in Phase 1/2 studies for various solid tumors. SGX has also developed a preclinical pipeline of novel oncology therapeutics using SGX FAST(TM) technology, a proprietary fragment-based approach to lead generation. The SGX preclinical oncology pipeline comprises novel inhibitors of wild-type and Gleevec(R) resistant mutants of BCR-ABL (importantly, T315I) and dual specificity inhibitors of the MET-RON receptor tyrosine kinases. SGX is also pursuing a broad program of fragment-based lead generation directed against a portfolio of validated oncology targets that include HSP-90 and the Aurora kinases. SGX has secured revenue generating drug discovery and development partnerships with leading pharmaceutical and biotechnology companies including Eli Lilly, Serono S.A., and Roche. For more information, please visit the company's website at www.stromix.com.
About the NIGMS Protein Structure Initiative
For more information about the NIGMS Protein Structure Initiative, visit www.nigms.nih.gov/psi/ |
| BioTech / BioMedical / Medical |
|
|
| |
| Wednesday, November 19, 2008 |
 |
|
Seven Investigator-Initiated Clinical Studies Announced Posted 7:09 AM PST
|
| |
| Tuesday, November 18, 2008 |
|
|
TorreyPines Therapeutics Licenses Posiphen , Bisnorcymcerine and Phenserine to QR Pharma Posted 3:00 PM PST
IntelliDOT Corporation Signs Agreement With Iatric Systems, Inc. to Simplify Provisioning of Interfaces for MEDITECH Hospitals Posted 8:08 AM PST
Aperio Receives Second FDA Clearance for Diagnosis of Digital Breast Cancer Slides Posted 7:40 AM PST
Aethlon Medical Releases Shareholder Letter Posted 7:39 AM PST
|
| |
| Monday, November 17, 2008 |
|
|
Prometheus Presents New Clinical Insights Into Diagnosis of Crohn's Disease in Children from Analysis of PROMETHEUS IBD Serology 7 Test Results Posted 3:45 PM PST
Abingdon Life Sciences, Inc. Extends Strategic Alliance With Stason Pharmaceuticals, Inc. to Provide Regulatory and Clinical Support to Asian Pharmaceutical and Biotech Companies Posted 6:38 AM PST
Hepatitis C Therapeutic DNA Vaccine Delivered by Inovio Biomedical's Electroporation Technology Reduces Viral Load by Up to 99.7% Posted 6:03 AM PST
|
| |
| Friday, November 14, 2008 |
|
|
CardioDynamics Announces Two Significant Studies Correlating BioZ(R) With Ejection Fraction (EF) Posted 9:41 AM PST
|
| |
| Thursday, November 13, 2008 |
|
|
MedImpact Celebrates Opening of Operations and Data Center Posted 2:29 PM PST
Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated Posted 2:28 PM PST
Cytori Receives First StemSourceŽ Cell Bank Order from Green Hospital Supply Posted 6:08 AM PST
Genoptix Ranked Ninth Fastest-Growing Company in North America on Deloitte's 2008 Technology Fast 500 Posted 6:02 AM PST
|
| |
| Wednesday, November 12, 2008 |
|
|
Vical Completes Enrollment and Reports Positive Interim Data in CMV Vaccine Phase 2 Trial Posted 10:02 AM PST
Illumina Launches Infinium HD Human660W-Quad BeadChip for Advancing Copy Number Variation Analysis Studies Posted 5:51 AM PST
|
| |
| Tuesday, November 11, 2008 |
|
|
Cardium's InnerCool Announces New Tissue-Specific UroCool(TM) System for Use in Prostate Surgeries Posted 10:10 AM PST
Invitrogen, BayBio Sign Partnership Agreement Posted 6:24 AM PST
|
| |
| Monday, November 10, 2008 |
|
|
Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction Posted 4:38 PM PST
Optimer Pharmaceuticals Reports Positive Data from its North American Phase 3 CDI Study of OPT-80 Posted 1:42 PM PST
Duska Therapeutics and DSM Pharmaceuticals in Manufacturing Collaboration for PSVT Drug Product Posted 1:37 PM PST
TorreyPines Therapeutics Sells Alzheimer's Disease Genetics Program to Eisai Posted 11:05 AM PST
High Resolution Nucleic Acid Separation Technologies Capture Significant Share in Large Nucleic Acid Electrophoresis Market Posted 6:41 AM PST
|
| |
| Friday, November 7, 2008 |
|
|
Nanogen Partners with Menarini to Capture European Molecular Diagnostic Market Posted 11:22 AM PST
Illumina Announces Breakthrough Human Genome Sequencing Studies Published in Nature Posted 5:20 AM PST
|
| |
| Thursday, November 6, 2008 |
|
|
Illumina Launches the HumanCytoSNP-12 BeadChip Posted 11:00 AM PST
JMAR Technologies Joins Homeland Security Effort to Create Advanced Cargo-Inspection Software Posted 8:10 AM PST
SkinMedica Launches TNS Essential Serum(TM) Posted 8:06 AM PST
Invitrogen Launches Microarray to Study Non-Coding RNA Posted 5:57 AM PST
Akesis Pharmaceuticals Announces Pipeline Expansion Strategy Posted 5:44 AM PST
|
|
|
|
|
|
FreshNews.com Jobs Change DAILY
We Have 5,000 + Job Listings! Open Your FREE Account
Employers or Job Searchers Get Started Now! Click Here
|
